Population-Level Risk-Benefit Analysis

Published on August 20, 2021

A population-level risk-benefit assessment was conducted to quantify the age-specific risks and benefits of resuming vaccination with Janssen (Johnson & Johnson) COVID-19 vaccine.

Continue reading on website
Other news

Use of Rapid Antigen Testing for SARS-CoV-2 in Remote Communities - Yukon-Kuskokwim Delta Region, Alaska, September 15, 2020-March 1, 2021

August 19, 2021
This report describes the use of COVID-19 rapid antigen testing in remote Alaskan communities.

Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 20 Aug 2021 06:00:00 EST

August 20, 2021
Total Doses Distributed = 426,106,115. Total Doses Administered = 360,634,287. Number of People Receiving 1 or More Doses = 200,421,787. Number of People Fully Vaccinated = 169,998,983.